Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis

Onassis Cardiac Surgery Center, Athens, Greece.
Autoimmunity reviews (Impact Factor: 7.93). 05/2012; 12(2). DOI: 10.1016/j.autrev.2012.05.005
Source: PubMed


Autoimmune responses and inflammation are involved in the excess cardiovascular risk observed in patients with systemic inflammatory diseases. Autoimmune myocarditis is a presentation of an inflammatory reaction of the heart during the course of autoimmune disorders, with most cases seen in systemic lupus erythematosus. Early diagnosis is of great significance because of the likelihood of progression to severe and potentially fatal complications such as arrhythmias, heart block, and heart failure. The clinical presentation of the disease is silent leading to delayed diagnosis when dilated cardiomyopathy or heart failure has already advanced. Therefore, a major issue is whether the diagnosis of myocarditis will continue to require invasive procedures such as endomyocardial biopsy or can be achieved with non-invasive methods. There is increasing evidence that noninvasive cardiac imaging, including tissue Doppler echocardiography and cardiac magnetic resonance (CMR), is able to detect subclinical cases and aid in the initiation of specific treatment when it is more likely to be effective. CMR in particular, has emerged as an important technique in the evaluation of myocarditis using three types of images: T2-weighted (T2-W), early T1-weighted (EGE) images taken after 1min, and delayed enhanced images (LGE) taken 15min after the injection of contrast agent. If 2/3 of the imaging sequences are positive, myocardial inflammation can be predicted or ruled out with a diagnostic accuracy of 78%. As our understanding of disease mechanisms improves, multimodality imaging may aid in the development of new diagnostic and therapeutic strategies for this potentially devastating complication of systemic inflammation, but further studies are needed to formally evaluate this.

Download full-text


Available from: Theodoros Dimitroulas, Aug 11, 2015
  • Source
    • "In that respect, the utilization of biochemical markers [24] [25] and modern imaging modalities [26] [27] for the noninvasive CVD assessment and risk stratification for RA patients has attracted the interest of rheumatologists, cardiologists, and radiologists. The currently available data suggest that there is room for the introduction of novel diagnostic protocols based on imaging methods; however, such strategies need to be validated in large, well-controlled studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with rheumatoid arthritis (RA) exhibit a high risk of cardiovascular disease (CVD). CVD in RA can present in many guises, commonly detected at a subclinical level only. Modern imaging modalities that allow the noninvasive assessment of myocardial performance and are able to identify cardiac abnormalities in early asymptomatic stages may be useful tools in terms of screening, diagnostic evaluation, and risk stratification in RA. The currently used imaging techniques are echocardiography, single-photon emission computed tomography (SPECT), and cardiac magnetic resonance (CMR). Between them, echocardiography provides information about cardiac function, valves, and perfusion; SPECT provides information about myocardial perfusion and carries a high amount of radiation; and CMR-the most promising imaging modality-evaluates myocardial function, inflammation, microvascular dysfunction, valvular disease, perfusion, and presence of scar. Depending on availability, expertise, and clinical queries, "right technique should be applied for the right patient at the right time." In this review, we present a short overview of CVD in RA focusing on the clinical implication of multimodality imaging and mainly on the evolving role of CMR in identifying high-risk patients who could benefit from prevention strategies and early specific treatment targeting the heart. Advantages and disadvantages of each imaging technique in the evaluation of RA are discussed.
    Full-text · Article · Jun 2013 · Seminars in arthritis and rheumatism
  • Source
    • "A recent meta-analysis showed that surrogate markers of atherosclerosis are more common in patients with SSc [110], but further investigations, including prospective studies of coronary heart disease in SSc, are warranted to define the potential connection between these conditions and to explore the relative contribution of SSc-specific factors, such as endothelial dysfunction, microvascular insult, autoimmunity, and systemic inflammation. The advent of novel diagnostic methods [111] and surrogate markers of cardiovascular disease [112] [113] may help quantify the burden of both, cardiac remodeling and atherosclerosis in patients with SSc. However, their integration into the current diagnostic workup is challenging and needs to be evaluated in large population-based studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac involvement in systemic sclerosis (SSc) is a frequent visceral complication that considerably affects the prognosis of the disease. The pathophysiologic hallmark is myocardial fibrosis which can progress leading to arrhythmia, right and/or left heart dysfunction and failure. Symptoms range from unusual to prominent and from mild to dramatic, but clinically overt disease is a poor prognostic factor. Primary myocardial involvement is related to focal ischemia due to transient coronary spasm, and the available data supports that microvascular functional and structural abnormalities rather than macrovascular coronary involvement represent the main underlying mechanism of the disease. However, the existence and prevalence of atherosclerotic coronary artery disease in SSc remains to be determined, as several studies have generated conflicting reports. Despite the lack of effective targeted therapy for SSc itself, sensitive and quantitative techniques have demonstrated the ability of vasodilators to improve myocardial function and perfusion and to prevent the evolution of subclinical heart involvement to decompensated heart failure. Further research will provide a better understanding of the disease by detecting the potent contribution of coronary artery involvement, explaining differences in accelerated atherosclerosis between SSc and other autoimmune disorders, and opening directions for the development of novel treatment strategies for this life-threatening complication of SSc.
    Full-text · Article · Apr 2013 · Current pharmaceutical design
  • Source
    • "Both scleroderma cardiac disease and pulmonary hypertension exhibit few symptoms and outward clinical signs but when clinically established, they convey poor prognosis, representing the leading cause of death in SSc [82]. The early detection of cardiopulmonary involvement by simple, non-invasive methods is clearly desirable and recently the introduction of biochemical markers [83,84] and more sophisticated imaging modalities [85,86] have improved our ability to detect subclinical disease and accordingly, refer high-risk patients for further investigations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The last few decades have witnessed an increased life expectancy of patients suffering with systemic rheumatic diseases, mainly due to improved management, advanced therapies and preventative measures. However, autoimmune disorders are associated with significantly enhanced cardiovascular morbidity and mortality not fully explained by traditional cardiovascular disease (CVD) risk factors. It has been suggested that interactions between high-grade systemic inflammation and the vasculature lead to endothelial dysfunction and atherosclerosis, which may account for the excess risk for CVD events in this population. Diminished nitric oxide synthesis-due to down regulation of endothelial nitric oxide synthase-appears to play a prominent role in the imbalance between vasoactive factors, the consequent impairment of the endothelial hemostasis and the early development of atherosclerosis. Asymmetric dimethylarginine (ADMA) is one of the most potent endogenous inhibitors of the three isoforms of nitric oxide synthase and it is a newly discovered risk factor in the setting of diseases associated with endothelial dysfunction and adverse cardiovascular events. In the context of systemic inflammatory disorders there is increasing evidence that ADMA contributes to the vascular changes and to endothelial cell abnormalities, as several studies have revealed derangement of nitric oxide/ADMA pathway in different disease subsets. In this article we discuss the role of endothelial dysfunction in patients with rheumatic diseases, with a specific focus on the nitric oxide/ADMA system and we provide an overview on the literature pertaining to ADMA as a surrogate marker of subclinical vascular disease.
    Full-text · Article · Dec 2012 · International Journal of Molecular Sciences
Show more